Integral Diagnostics Ltd. (AU:IDX)
ASX:IDX
IDX Stock Chart & Stats
AU$2.43
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.43
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$2.11 - AU$3.07
Previous CloseN/A
Volume920.11K
Average Volume (3M)911.20K
Market Cap
AU$905.69M
Enterprise ValueAU$1.68B
Total Cash (Recent Filing)AU$34.12M
Total Debt (Recent Filing)AU$841.54M
Price to Earnings (P/E)26.4
Beta0.41
Next Earnings
Aug 31, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend Yield2.65%
Share Statistics
EPS (TTM)0.02
Shares Outstanding372,926,670
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.57
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.25Price Target Upside33.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.13
Revenue Forecast (FY)AU$801.31M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth (27.66% in the latest year) indicates rising scan volumes and service demand across IDX's clinic network. Durable top-line expansion supports scale benefits, higher utilization and capacity to invest in equipment and clinics, strengthening long-term service reach.
High Gross Margin / Operational EfficiencyExceptionally high gross margin (95.52%) reflects structural advantages: low direct costs per exam and value-added reporting services. This margin profile provides durable operating leverage, enabling investment in technology and staffing while buffering against payor pricing pressure if overhead is managed.
Improved Leverage / Balance SheetAn improved debt-to-equity ratio of 0.84 signals stronger balance-sheet positioning versus prior periods. Lower relative leverage enhances financial flexibility for capex, M&A or clinic expansion, reduces refinancing risk, and supports medium-term strategic investments without overly straining cash flow.
Bears Say
Low Net ProfitabilityA net margin around 0.75% shows limited ability to convert high gross profit into retained earnings. Persistently weak net profitability constrains retained capital for growth, dividend capacity and buffers against downturns, implying management must materially improve overhead or pricing to lift returns.
Declining Free Cash FlowA near 59% drop in free cash flow weakens the firm's ability to fund capex, acquisitions and shareholder returns from operations. Even with positive operating cash flow, falling FCF-to-income ratios create structural liquidity pressure and may force reliance on debt or equity for strategic spending.
Low Return On EquityROE of 0.67% indicates poor capital efficiency despite revenue growth. Low shareholder returns suggest investment spending or operating costs are not generating proportional profits, a structural governance and execution issue that must be addressed to attract long-term capital.
Integral Diagnostics Ltd. News
IDX FAQ
What was Integral Diagnostics Ltd.’s price range in the past 12 months?
Integral Diagnostics Ltd. lowest share price was AU$2.11 and its highest was AU$3.07 in the past 12 months.
What is Integral Diagnostics Ltd.’s market cap?
Integral Diagnostics Ltd.’s market cap is AU$905.69M.
When is Integral Diagnostics Ltd.’s upcoming earnings report date?
Integral Diagnostics Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 159 days.
How were Integral Diagnostics Ltd.’s earnings last quarter?
Integral Diagnostics Ltd. released its earnings results on Feb 23, 2026. The company reported AU$0.024 earnings per share for the quarter, missing the consensus estimate of AU$0.056 by -AU$0.032.
Is Integral Diagnostics Ltd. overvalued?
According to Wall Street analysts Integral Diagnostics Ltd.’s price is currently Undervalued.
Does Integral Diagnostics Ltd. pay dividends?
Integral Diagnostics Ltd. pays a Semiannually dividend of AU$0.04 which represents an annual dividend yield of 2.65%. See more information on Integral Diagnostics Ltd. dividends here
What is Integral Diagnostics Ltd.’s EPS estimate?
Integral Diagnostics Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Integral Diagnostics Ltd. have?
Integral Diagnostics Ltd. has 372,926,670 shares outstanding.
What happened to Integral Diagnostics Ltd.’s price movement after its last earnings report?
Integral Diagnostics Ltd. reported an EPS of AU$0.024 in its last earnings report, missing expectations of AU$0.056. Following the earnings report the stock price went down -5.83%.
Which hedge fund is a major shareholder of Integral Diagnostics Ltd.?
Currently, no hedge funds are holding shares in AU:IDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integral Diagnostics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$3.25 (33.74% Upside)
AU$3.25 (33.74% Upside)
Blogger Sentiment
Bullish
AU:IDX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$185.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.34%
12-Months-Change
Fundamentals
Return on Equity
2.05%
Trailing 12-Months
Asset Growth
4.81%
Trailing 12-Months
Company Description
Integral Diagnostics Ltd.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides services through 67 radiology clinics. The company was incorporated in 2008 and is headquartered in Melbourne, Australia.
IDX Stock 12 Month Forecast
Average Price Target
AU$3.25
▲(33.74% Upside)
Technical Analysis
Healius Limited
―
Genetic Signatures Ltd.
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---